Market closed
Karyopharm Therapeutics/$KPTI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Ticker
$KPTI
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
279
ISIN
US48576U2050
Website
KPTI Metrics
BasicAdvanced
$52M
-
-$14.00
0.11
-
Price and volume
Market cap
$52M
Beta
0.11
52-week high
$10.38
52-week low
$3.51
Average daily volume
117K
Financial strength
Current ratio
1.696
Quick ratio
1.512
Long term debt to equity
-130.719
Total debt to equity
-144.085
Interest coverage (TTM)
-3.19%
Management effectiveness
Return on assets (TTM)
-36.88%
Return on equity (TTM)
47.43%
Valuation
Price to revenue (TTM)
0.336
Price to book
-0.27
Price to tangible book (TTM)
-0.27
Price to free cash flow (TTM)
-0.383
Growth
Revenue change (TTM)
-0.55%
Earnings per share change (TTM)
-25.48%
3-year revenue growth (CAGR)
-11.54%
3-year earnings per share growth (CAGR)
-17.29%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Karyopharm Therapeutics stock?
Karyopharm Therapeutics (KPTI) has a market cap of $52M as of May 13, 2025.
What is the P/E ratio for Karyopharm Therapeutics stock?
The price to earnings (P/E) ratio for Karyopharm Therapeutics (KPTI) stock is 0 as of May 13, 2025.
Does Karyopharm Therapeutics stock pay dividends?
No, Karyopharm Therapeutics (KPTI) stock does not pay dividends to its shareholders as of May 13, 2025.
When is the next Karyopharm Therapeutics dividend payment date?
Karyopharm Therapeutics (KPTI) stock does not pay dividends to its shareholders.
What is the beta indicator for Karyopharm Therapeutics?
Karyopharm Therapeutics (KPTI) has a beta rating of 0.11. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.